Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: Implications for combinatorial treatment regimen with chemotherapeutic agents

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7195-7202

  Mantwill, Klaus ^a   Köhler Vargas, Nadia ^a   Bernshausen, Alexandra ^a   Bieler, Alexa ^a   Lage, Hermann ^c   Kaszubiak, Alexander ^c   Surowiak, Pavel ^c   Dravits, Tanja ^a   Treiber, Uwe ^a   Hartung, Rudolf ^a   Gansbacher, Bernd ^a   Holm, Per S ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b XVir Therapeutics GmbH   (Germany)

^c Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; GLYCOPROTEIN E2; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN E1B55K; VIRUS PROTEIN E4ORF6; Y BOX BINDING PROTEIN 1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE S PHASE; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT; VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E2 PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEUS; COMBINED MODALITY THERAPY; DAUNORUBICIN; DNA-BINDING PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; TAXOIDS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746911091     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2339     Document Type: Article

References (50)

1. Gottesmann MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
3. Swamynathan SK, Nambiar A, Guntaka RV. Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes. FASEB J 1998;12:515-22.
4. Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997;3:447-50.
5. Stein U, Jurchott K, Walther W, et al. Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 2001;276:28562-9.
6. Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997;417:390-4.
7. Ohga T, Uchiumi T, Makino Y, et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998;273:5997-6000.
8. Uchiumi T, Kohno K, Tanimuira H, et al. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth Differ 1993;4:147-57.
9. Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 1998;8:318-23.
10. Wolffe AP. Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bioessays 1994;16:245-51.
11. Gaudreault I, Guay D, Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 2004;32:316-27.
12. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein YB-1. Bioessays 2003;25:691-8.
13. Oda Y, Ohishi Y, Saito T, et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase IIα expression, and with poor prognosis in synovial sarcoma. J Pathol 2003;199:251-8.
14. Janz M, Harbek N, Dettmar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97:278-82.
15. Schibao K, Takano H, Nakayama Y, et al. Enhanced compression of YB-1 and DNA toposiomerase IIα genes in human colorectal carcinomas. Int J Cancer 1999;10:732-7.
16. Huang X, Ushijima K, Komai K, et al. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol 2004;93:287-91.
17. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004;59:337-49.
18. Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7:3151-5.
19. Levenson VV, Davidovich IA, Roninson IB. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 2000;60:5027-30.
20. Okamoto T, Izumi H, Imamura T, et al. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression Oncogene 2000;19:6194-202.
21. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 2000;252:1-13.
22. Ladomery M, Sommerville J. A role for Y-box proteins in cell proliferation. Bioessays 1995;17:9-11.
23. Lasham A, Moloney S, Hale T, et al. The Y-box-binding protein, YB-1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 2003;278:35516-23.
24. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
25. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
26. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001;61:517-25.
27. Holm PS, Bergmann S, Jurchott K, et al. YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem 2002;277:10427-34.
28. Holm PS, Lage H, Bergmann S, et al. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res 2004;64:322-8.
29. Swaminathan S, Thimmapaya B. Regulation of adenovirus E2 transcription unit. Curr Top Microbiol Immunol 1995;199:177-94.
30. Bhat G, Raman LS, Murthy S, Domer P, Thimmapaya B. In vivo identification of multiple promoter domains of adenovirus EIIA-late promoter. EMBO J 1987;6:2045-52.
31. Kovesdi I, Reichel R, Nevins JR. Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci U S A 1987;84:2180-4.
32. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-312.
33. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 1990;50:6100-6.
34. Holm PS, Scanlon KJ, Dietel M. Reversion of multidrug resistance in the P-glycoprotein positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 1994;70:239-43.
35. Chow LT, Broker TR, Lewis JB. Complex splicing patterns of RNAs from the early regions of adenovirus-2. J Biol Chem 1979;134:265-303.
36. Ben-Israel H, Kleinberger T. Adenoviruses and cell cycle control. Front Biosci 2002;7:1369-95.
37. Nevins JR. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981;26:213-20.
38. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003;22:7512-23.
39. You L, Yang CT, Jablons DM. Onyx-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Cancer Res 2000;60:1009-13.
40. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001;61:5453-60.
41. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 2004;78:12243-51.
42. Del Valle L, Azizi SA, Krynska B, Enam S, Croul SE, Khalili K. Reactivation of human neurotropic JC virus expressing oncogenic protein in a recurrent glioblastoma multiforme. Ann Neurol 2000;48:932-6.
43. Hipfel R, Schittek B, Bodingbauer Y, Garbe C. Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization. Br J Cancer 2000;82:1149-57.
44. Jurchott K, Bergmann S, Stein U, et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003;278:27988-96.
45. 102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells [tadvanced online publication]. Oncogene 2005 Apr.
46. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
47. Heise C, Sampson-Johannes A, Williams A, et al. Onyx-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
48. Zeng M, Cerniglia GJ, Eck SL, Stevens CW. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionising radiation. Hum Gene Ther 1997;10:1025-32.
49. Bieler A, Mantwill K, Dravits T, et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 2006;17:55-70.
50. Toth K, Tarakaova V, Doronin K, et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E311.6K) protein. Cancer Gene Ther 2003;10:193-200.